Chapter 14 in Haematology
(chronic myeloid leukaemia) summary
-Chronic myeloid leukaemia is a clonal disorder of a pluripotent steam cell. The disease accounts
for around 15 %of leukamias and may occur at anu age.
-All cases of CML have a transloction between chromosomes 9 and 22. This leads to the BCP hene
on chrosome 22 and generates the philadelphia chromosome.
-The
resulting chimeric BCR-ABL1 gene codes for a fusion protien with tyrosine
kinase activity.
-In some patients the phildaelphia examination of tumour cells but the only be detected
by FISH or PCR.
-The disease can occur at any age but is most common between the ages of 40 and 60 years.
-The clinical feauters include anaemia bleeding and splenomegaly. There is usually a marked
neutrophlia with myelocytes and basophils seen in the blood film.
-Transformation to an accelerated phase or acyte leukaemia may occur.
-Treatement is with tyrosine kinase inhibitors such as imatinib,dasatinib or
nilotinib.tumour cells can acquired resistance totreatment and drug therapy is
tailpred in response to this.
-Stem cell transplantation can be
curative and may also be useful for advanced disease.
-The clinical outlook is now
very good and patient can expect long-term control of disease.
-Chronic eosinophilic and neutrophil leukaemia are much rare.
From
book: Essentail Haematology A.V.HOFFBRAND,P.A.H.MOSS.6EDITION
Comments
Post a Comment